ICICI Securities maintains a 'Sell' call on Biocon, setting a revised target price of Rs 270. Despite a projected earnings CAGR of 91.6% dr...

Axis Securities recommends a Buy call on Biocon, setting a target price of Rs 351, indicating a potential 10% upside. The recommendation is...

Motilal Oswal Financial Services has recommended a buy on Biocon, targeting a price of Rs 430. The company, a leader in the pharmaceuticals...

"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...

Biocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 26389.19 Crore) operating in Pharmaceuticals secto...

Given the multiple near-term levers, enviable biosimilars pipeline, strengthening of leadership teams, favourable valuation and marquee inv...

Biocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 28934.46 Crore) operating in Pharmaceuticals secto...

The analyst suggested a stoploss at Rs 300.

The analyst suggested a stoploss at Rs 300 .

The company’s third quarter result was operationally in line with estimates but a higher tax rate led to a 10% miss on reported profit.

The analyst suggested a stoploss at Rs 293.

Sell Biocon Ltd. at a price target of Rs 270.0 and a stoploss at Rs 301 from entry point.

Mittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30.

Consolidated total income of the company stood at Rs 1,610.6 crore for the quarter under consideration.

Buy Biocon Ltd. at a price target of Rs 1234.0 and a stoploss at Rs 1107.0 from entry point

The topic of discussion 'Are We Heading Toward an Intolerant India Today?' reached no real conclusion and the panelists taking political po...

"We are working towards diversifying our regional dependencies to diminish the impact of such externalities," Biocon CMD Kiran Mazumdar-Sha...